Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 6735-6745 |
| Number of pages | 11 |
| Journal | Cancer Research |
| Volume | 70 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - 2010 |
| MoE publication type | A1 Journal article-refereed |
Fingerprint
Cite this
}
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. / Gupta, Santosh; Iljin, Kristiina; Sara, Henri; Mpindi, John; Mirtti, Tuomas; Vainio, Paula; Rantala, Juha K.; Alanen, Kalle; Nees, Matthias; Kallioniemi, Olli (Corresponding Author).
In: Cancer Research, Vol. 70, No. 17, 2010, p. 6735-6745.Research output: Contribution to journal › Article › Scientific › peer-review
TY - JOUR
T1 - FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells
AU - Gupta, Santosh
AU - Iljin, Kristiina
AU - Sara, Henri
AU - Mpindi, John
AU - Mirtti, Tuomas
AU - Vainio, Paula
AU - Rantala, Juha K.
AU - Alanen, Kalle
AU - Nees, Matthias
AU - Kallioniemi, Olli
PY - 2010
Y1 - 2010
N2 - TMPRSS2-ERG and other gene fusions involving ETS factors and genes with strong promoter elements are common in prostate cancer. Although ERG activation has been linked to invasive properties of prostate cancers, the precise mechanisms and pathways of ERG-mediated oncogenesis remain poorly understood. Here, we show that ERG knockdown in VCaP prostate cancer cells causes an activation of cell adhesion, resulting in strongly induced active β1-integrin and E-cadherin expression as well as changes in WNT signaling. These observations were corroborated by data from ERG-overexpressing nontransformed prostate epithelial cells as well as gene expression data from clinical prostate cancer samples, which both indicated a link between ERG and epithelial-to-mesenchymal transition (EMT). Upregulation of several WNT pathway members was seen in ERG-positive prostate cancers, with frizzled-4 (FZD4) showing the strongest overexpression as verified by both reverse transcription-PCR and immunostaining. Both ERG knockin and knockdown modulated the levels of FZD4 expression. FZD4 silencing could mimic the ERG knockdown phenotype by inducing active β1-integrin and E-cadherin expression, whereas FZD4 overexpression reversed the phenotypic effects seen with ERG knockdown. Taken together, our results provide mechanistic insights to ERG oncogenesis in prostate cancer, involving activation of WNT signaling through FZD4, leading to cancer-promoting phenotypic effects, including EMT and loss of cell adhesion.
AB - TMPRSS2-ERG and other gene fusions involving ETS factors and genes with strong promoter elements are common in prostate cancer. Although ERG activation has been linked to invasive properties of prostate cancers, the precise mechanisms and pathways of ERG-mediated oncogenesis remain poorly understood. Here, we show that ERG knockdown in VCaP prostate cancer cells causes an activation of cell adhesion, resulting in strongly induced active β1-integrin and E-cadherin expression as well as changes in WNT signaling. These observations were corroborated by data from ERG-overexpressing nontransformed prostate epithelial cells as well as gene expression data from clinical prostate cancer samples, which both indicated a link between ERG and epithelial-to-mesenchymal transition (EMT). Upregulation of several WNT pathway members was seen in ERG-positive prostate cancers, with frizzled-4 (FZD4) showing the strongest overexpression as verified by both reverse transcription-PCR and immunostaining. Both ERG knockin and knockdown modulated the levels of FZD4 expression. FZD4 silencing could mimic the ERG knockdown phenotype by inducing active β1-integrin and E-cadherin expression, whereas FZD4 overexpression reversed the phenotypic effects seen with ERG knockdown. Taken together, our results provide mechanistic insights to ERG oncogenesis in prostate cancer, involving activation of WNT signaling through FZD4, leading to cancer-promoting phenotypic effects, including EMT and loss of cell adhesion.
U2 - 10.1158/0008-5472.CAN-10-0244
DO - 10.1158/0008-5472.CAN-10-0244
M3 - Article
VL - 70
SP - 6735
EP - 6745
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 17
ER -